Moreover, concurrently targeting EZH2 exhibited a synergistic effect with CYH33 against ESCC cells as well as PDXs, which provided the mechanistic rationale for combining CYH33 with EZH2 inhibitors for ESCC treatment (Figure 6G). Here, EZH2 is linked to esophageal squamous cell carcinoma.